Clinical trial NCT00198380 - References

Lung Adenocarcinoma With Bronchiolo-alveolar Feature — Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Citation(s)

•   Cadranel J, Lavole A, Gounant V, Wislez M
  [Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S165-70. French.
•   Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC, Morin F, Milleron B; IFCT-0401 Trial Group
  IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with
•   Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR
  The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol. 2006 May;1(4):344-59. Erratum In: J Thorac Oncol. 2006 Jun;1(5):405.
•   Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J
  Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in
•   Wislez M, Massiani MA, Milleron B, Souidi A, Carette MF, Antoine M, Cadranel J
  Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest. 2003 Jun;123(6):1868-77. doi: 10.1378/chest.123.6.1868.

Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)

Details for clinical trial NCT00198380